Numbers

Claude View

The Numbers

Ugro Capital trades at ₹94 – 0.59x book value and 52% below its 52-week high of ₹196 – because the market sees an 8% ROE NBFC that has never generated returns above its cost of equity and is mid-pivot away from its co-lending income model. The single metric that will rerate or derate this stock is ROA: if it climbs from ~1.6% toward 3.5-4% as management guides, the P/B re-rates from 0.6x toward 1.5x+. If it stalls, the 0.6x discount becomes a trap.

Revenue and Earnings Power

Revenue has compounded at 74% CAGR over FY2021-FY2025, driven entirely by loan book expansion. PAT remains thin at ₹144 Cr on ₹1,396 Cr revenue – a 10.3% net margin reflecting the high cost structure of a scaling NBFC. Revenue growth has decelerated from 119% (FY2023) to 29% (FY2025) as the base catches up, while profit growth accelerated from ₹40 Cr to ₹144 Cr as operating leverage begins.

The ROE Problem – And the Path Out

UGRO has never earned above its cost of equity. At 8% ROE, the 0.59x P/B is mathematically justified – an NBFC earning below COE should trade below book. Management targets 4% ROA and 18% ROE by end of FY2028 through four simultaneous levers: yield mix shift (14% to 19%), ₹220 Cr cost reduction, leverage increase (3.3x to 5x), and sub-2% credit costs. Each lever carries execution risk.

Balance Sheet: Leverage Still Conservative

Leverage at 3.3x is well below the 4-6x at which NBFC peers operate. CRAR at 20.8% provides a 580 bps buffer over the 15% regulatory minimum. This headroom is a profitability lever – each 1x increase in leverage adds ~2-3% to ROE at current spreads – but requires stable asset quality before deployment. The Profectus acquisition (₹1,400 Cr all-cash) consumed recent equity raises but adds ~₹150 Cr annualized profit and is CRAR-accretive.

Equity Dilution: The Per-Share Drag

Equity capital jumped 24% from ₹92 Cr to ₹114 Cr between FY2025 and H1 FY2026 via rights issue (₹381 Cr) and preferential allotment (₹911 Cr). This funded the Profectus acquisition but diluted per-share economics. Book value per share at ₹159 has not kept pace with total equity growth from ₹2,046 Cr to ₹2,463 Cr. Management says no further capital raise needed for 18-24 months – if this holds, per-share accretion can finally begin.

Asset Quality: Stable but Untested at Scale

GNPA peaked at 2.5% in Q1 FY2026 and improved to 2.2% by December 2025 after UGRO cut off sub-₹7.5 lakh micro-loans and tightened approval rates from 30% to 20%. Provision coverage at 47% is adequate but not generous. Management guides GNPA stabilizing at 2.5% with credit costs around 2% through the cycle. The embedded finance book (26% yield) carries sub-0.5% GNPA – risk is concentrated in the legacy intermediated segment being wound down.

The Critical Chart: Yield Mix Shift

Shareholding: FII Conviction Rising, Then Retreating

FII ownership surged from 7% (FY2023) to 29% (Q1 FY2026) before retreating sharply to 23% in Q3 FY2026 – coinciding with the stock's decline from ₹196 to ₹94. Promoter holding at 1.7% is the lowest among listed NBFC peers and raises alignment questions. DII participation is negligible at 1.4%.

Peer Valuation Map

The scatter tells the story. UGRO sits in the bottom-left: lowest ROE, lowest P/B. Five-Star at 18.6% ROE and 1.82x P/B is the closest operational comp and the aspirational target. Note that CreditAccess and IIFL trade at 2.7x+ book despite sub-8% ROE – scale and franchise trust command premiums UGRO has not yet earned. Every 1% ROE improvement should mechanically close the P/B gap by ~0.15x.

Cost Structure: The Operating Leverage Opportunity

Interest costs consume 45% of revenue and opex another 40%, leaving just 10% PAT margin. The ₹220 Cr annualized cost rationalization (cutting DSA-led verticals) targets opex/revenue below 35%. Combined with yield improvement, PAT margins should expand toward 18-20% by FY2028 if execution delivers. This is the operating leverage inflection the market is waiting for – but it has not arrived yet.

What the Numbers Confirm, Contradict, and Demand

The numbers confirm UGRO has built real scale fast – ₹15,454 Cr AUM, 300+ branches, A+ credit rating, 40% YoY AUM growth, and improving GNPA from 2.5% to 2.2%. Analyst consensus targets range from ₹237 to ₹313, implying 150-230% upside from current levels.

The numbers contradict the idea that this is already a profitable franchise. An 8% ROE at 3.3x leverage is mediocre. Standalone Q3 PAT of ₹6 Cr raises legitimate questions about earnings quality without co-lending income. The 24% equity dilution in H1 FY2026 and 52% stock decline from highs show the market's skepticism is deep and justified until proven wrong.

Watch next quarter: Consolidated Q4 FY2026 PAT and the post-Profectus NII run-rate. If consolidated quarterly PAT crosses ₹60 Cr with stable GNPA below 2.5%, the ROE-to-rerating math starts working. If it stalls below ₹40 Cr, the 0.6x P/B stays.